Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Capital Expenditures (2016 - 2023)

Historic Capital Expenditures for Alaunos Therapeutics (TCRT) over the last 13 years, with Q3 2023 value amounting to $1000.0.

  • Alaunos Therapeutics' Capital Expenditures fell 9961.83% to $1000.0 in Q3 2023 from the same period last year, while for Jun 2024 it was $1000.0, marking a year-over-year decrease of 9969.33%. This contributed to the annual value of $197000.0 for FY2023, which is 879.63% down from last year.
  • Latest data reveals that Alaunos Therapeutics reported Capital Expenditures of $1000.0 as of Q3 2023, which was down 9961.83% from $95000.0 recorded in Q2 2023.
  • In the past 5 years, Alaunos Therapeutics' Capital Expenditures registered a high of $3.8 million during Q4 2020, and its lowest value of -$132000.0 during Q4 2022.
  • Over the past 5 years, Alaunos Therapeutics' median Capital Expenditures value was $310500.0 (recorded in 2021), while the average stood at $845250.0.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 2293000.0% in 2020, then crashed by 13676.88% in 2022.
  • Alaunos Therapeutics' Capital Expenditures (Quarter) stood at $10000.0 in 2019, then soared by 37560.0% to $3.8 million in 2020, then crashed by 90.47% to $359000.0 in 2021, then crashed by 136.77% to -$132000.0 in 2022, then surged by 100.76% to $1000.0 in 2023.
  • Its last three reported values are $1000.0 in Q3 2023, $95000.0 for Q2 2023, and $101000.0 during Q1 2023.